Sunzen Group Berhad (“Sunzen” or “the Group”), formerly known as Sunzen Biotech Berhad and an established player in Malaysia’s health products, medical devices and services, and loan financing with a diversified portfolio, announced that all resolutions tabled at its Twentieth Annual General Meeting (“20th AGM”) held today at Kota Permai Golf & Country Club were duly passed by shareholders, reflecting broad confidence in the Group’s governance, strategic focus, and long-term plans.
During the AGM, shareholders received the Audited Financial Statements for the financial year ended 30 June 2025, together with the Directors’ and Auditors’ Reports. The meeting also approved the Directors’ fees and benefits for the financial year ending 30 June 2026. Furthermore, Shareholders re-elected Mr. Teo Yek Ming and Ms. Poo Long Yii as Directors of the Company, both of whom retired by rotation in accordance with the Company’s Constitution. Messrs. Grant Thornton Malaysia PLT was also re-appointed as the Group’s external auditors for the ensuing financial year, with the Board authorised to fix their remuneration.
Several important resolutions under special business were also adopted. Shareholders renewed the authority for the Directors to issue and allot shares of up to 10% of the Company’s total issued shares pursuant to Sections 75 and 76 of the Companies Act 2016, providing flexibility for future fundraising to support expansion, investments, or working capital. The meeting also approved the waiver of statutory pre-emptive rights in relation to this mandate.
Shareholders further approved the renewal of the authority for Sunzen to purchase up to 10% of its own shares on Bursa Malaysia Securities Berhad. This empowers the Board to execute purchases when appropriate and manage treasury shares strategically to enhance long-term shareholder value.
In addition, shareholders approved the continuation of Mr. Khoo Kien Hoe as Independent Non-Executive Director, allowing him to continue serving beyond nine years in recognition of his objectivity, business familiarity, and consistent contribution to the Board.
Group Managing Director of Sunzen Group Berhad, Mr. Teo Yek Ming commented, “We are deeply encouraged by the strong shareholder support received today. The approval of all resolutions reaffirms confidence in our strategic priorities across Human Health, Medical Devices and Services, and Loan Financing. As we move into the next phase of growth, we remain focused on operational discipline, product and segment scalability, and delivering sustainable value for our shareholders.”
The Board expressed its appreciation for shareholders’ continued trust and participation. The successful conclusion of the AGM reinforces Sunzen’s commitment to governance excellence, business resilience, and long-term sustainable growth across its diversified portfolio.
